531015 VENMAX

Venmax Drugs & Pharmaceuticals Share Price

₹23.81 -0.48 (-1.98%)

23 Feb, 2025 14:45

SIP TrendupStart SIP in VENMAX

Start SIP

Performance

  • Low
  • ₹0
  • High
  • ₹0
  • 52 Week Low
  • ₹0
  • 52 Week High
  • ₹0
  • Open Price₹0
  • Previous Close₹0
  • Volume0

Investment Returns

  • Over 1 Month -6.22%
  • Over 3 Month + 469.62%
  • Over 6 Month + 469.62%
  • Over 1 Year + 469.62%
SIP Lightning

Smart Investing Starts Here Start SIP with Venmax Drugs & Pharmaceuticals for Steady Growth!

Invest Now

Venmax Drugs & Pharmaceuticals Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

Venmax Drugs & Pharmaceuticals Financials

Venmax Drugs & Pharmaceuticals Technicals

EMA & SMA

Current Price
₹23.81
-0.48 (-1.98%)
pointer
  • stock-down_img
  • Bearish Moving Average 9
  • stock-up_img
  • Bullish Moving Average 7
  • 20 Day
  • ₹26.08
  • 50 Day
  • ₹22.31
  • 100 Day
  • ₹16.70
  • 200 Day
  • ₹11.69

Resistance and Support

23.81 Pivot Speed
  • R3 23.81
  • R2 23.81
  • R1 23.81
  • S1 23.81
  • S2 23.81
  • S3 23.81

What's your outlook on Venmax Drugs & Pharmaceuticals?

You can only vote for once

Ratings

Master Rating

EPS Strenth

N/A

Price Strength

Buyer Demand

Group Rank

Venmax Dg.And Pharms. has an operating revenue of Rs. 0.57 Cr. on a trailing 12-month basis. An annual revenue de-growth of -52% needs improvement, Pre-tax margin of 0% needs improvement, ROE of -9% is poor and needs improvement. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. From an O'Neil Methodology perspective, the stock has an EPS Rank of 0 which is a POOR score indicating inconsistency in earnings, a RS Rating of 99 which is GREAT indicating the outperformance as compared to other stocks, Buyer Demand at A+ which is evident from recent demand for the stock, Group Rank of 67 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of D is close to being the worst. Overall, the stock has some relative strength and buyer demand but we want to see further fundamental performance to qualify as a growth stock. Please note that this is a thinly traded stock.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Venmax Drugs & Pharmaceuticals Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2025-02-08 Quarterly Results
2025-01-11 Preferential issue of shares
2024-11-11 Quarterly Results
2024-08-12 Quarterly Results
2024-05-14 Audited Results

Venmax Drugs & Pharmaceuticals F&O

Venmax Drugs & Pharmaceuticals Shareholding Pattern

23.13%
0.15%
65.54%
11.18%

About Venmax Drugs & Pharmaceuticals

  • NSE Symbol
  • VENMAX
  • BSE Symbol
  • 531015
  • Managing Director
  • Mr. N Krishnaiah
  • ISIN
  • INE154G01022

Similar Stocks to Venmax Drugs & Pharmaceuticals

Venmax Drugs & Pharmaceuticals FAQs

Venmax Drugs & Pharmaceuticals share price is ₹23 As on 23 February, 2025 | 14:31

The Market Cap of Venmax Drugs & Pharmaceuticals is ₹12.5 Cr As on 23 February, 2025 | 14:31

The P/E ratio of Venmax Drugs & Pharmaceuticals is -16.8 As on 23 February, 2025 | 14:31

The PB ratio of Venmax Drugs & Pharmaceuticals is -19.2 As on 23 February, 2025 | 14:31

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23